Alzheimer's Disease
Conditions
Keywords
Efficacy, Safety, Pharmacokinetics, Alzheimer's disease
Brief summary
1. Assess the efficacy of varenicline, relative to placebo, on a performance based measure of cognition in patients with mild to moderate Alzheimer's disease 2. Evaluate the effects of varenicline on clinically relevant measures including attention and executive function, behavior, and clinician rated global change. 3. Evaluate the safety and tolerability of varenicline, relative to placebo, in patients with mild to moderate Alzheimer's disease 4. Evaluate the pharmacokinetics of varenicline in patients with mild to moderate Alzheimer's disease.
Interventions
0.5 mg once daily for 1 week followed by 0.5 mg twice daily for 1 week followed by 1 mg twice daily for 4 weeks
Placebo once daily for 1 week followed by placebo twice daily for 5 weeks.
Sponsors
Study design
Eligibility
Inclusion criteria
* Males or females, age 55-85 * Diagnosis of probable Alzheimer's disease, consistent with criteria from both: 1) National Institute of Neurological and Communicable Disease and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and 2) Diagnostic and Statistical Manual of Mental Disorders (DSM IV) * Mini-mental status exam score of 14-26 inclusive * Rosen-Modified Hachinski Ischemia Score of \< or = 4
Exclusion criteria
* Diagnosis or history of other dementia or neurodegenerative disorders * Diagnosis or history of clinically significant cerebrovascular or cardiovascular disease * Subjects with pulmonary disease or evidence of clinically significant pulmonary symptoms
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 6 | Week 6 | 12-item scale to assess severity of cognitive impairment in AD. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, remembering test instructions, and concentration/distractibility. Total score range from 0-75 with 75 indicating worse cognition. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 3 | Week 3 | 11-item scale designed to assess the severity of cognitive impairments in AD subjects. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, and remembering test instructions. Total score range from 0-70 with 70 indicating worse cognition. |
| Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 6 | Week 6 | 11-item scale designed to assess the severity of cognitive impairments in AD subjects. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, and remembering test instructions. Total score range from 0-70 with 70 indicating worse cognition. |
| Mean Clinical Global Impression - Improvement (CGI-I) Score at Week 6 | Week 6 | CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected. |
| Neuropsychiatric Inventory (NPI) Total Score at Week 3 | Week 3 | Caregiver interview-based rating scale assessing 12 behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, appetite/eating, and sleep. Each symptom score derived by frequency of symptoms \* severity of symptoms (range 0-12). Total score = sum of symptom scores; range: 0-144 with higher score indicating greater behavioral disturbances. |
| Neuropsychiatric Inventory (NPI) Total Score at Week 6 | Week 6 | Caregiver interview-based rating scale assessing 12 behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, appetite/eating, and sleep. Each symptom score derived by frequency of symptoms \* severity of symptoms (range 0-12). Total score = sum of symptom scores; range: 0-144 with higher score indicating greater behavioral disturbances. |
| Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 1 | Week 1 | Assessment of the cognitive domain psychomotor function through yes or no responses within 5 minutes to 30 trials; score range: 0 to 3.69. Performance variable: speed of performance; average of the log10 t transformed reaction time for correct responses. Reaction times longer than 5 seconds (log10 \[5000\]) were excluded as reflecting responses that were abnormally slow. |
| Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 3 | Week 3 | Assessment of the cognitive domain psychomotor function through yes or no responses within 5 minutes to 30 trials; score range: 0 to 3.69. Performance variable: speed of performance; average of the log10 t transformed reaction time for correct responses. Reaction times longer than 5 seconds (log10 \[5000\]) were excluded as reflecting responses that were abnormally slow. |
| Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 6 | Week 6 | Assessment of the cognitive domain psychomotor function through yes or no responses within 5 minutes to 30 trials; score range: 0 to 3.69. Performance variable: speed of performance; average of the log10 t transformed reaction time for correct responses. Reaction times longer than 5 seconds (log10 \[5000\]) were excluded as reflecting responses that were abnormally slow. |
| Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 1 | Week 1 | Assessment of the cognitive domain visual episodic memory (associate learning) through responses within 7 minutes to 4 targets x 4 rounds (mild AD) or 3 targets x 4 rounds (moderate AD); score range: 35 to 100. Performance variable: number of errors made in correctly placing each of the 4 patterns in their location four times. |
| Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 3 | Week 3 | Assessment of the cognitive domain visual episodic memory (associate learning) through responses within 7 minutes to 4 targets x 4 rounds (mild AD) or 3 targets x 4 rounds (moderate AD); score range: 35 to 100. Performance variable: number of errors made in correctly placing each of the 4 patterns in their location four times. |
| Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 3 | Week 3 | 12-item scale to assess severity of cognitive impairment in AD. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, remembering test instructions, and concentration/distractibility. Total score range from 0-75 with 75 indicating worse cognition. |
| Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 1 | Week 1 | Assessment of the cognitive domain working memory through yes or no responses to 30 trials within 5 minutes; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses. |
| Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 3 | Week 3 | Assessment of the cognitive domain working memory through yes or no responses to 30 trials within 5 minutes; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses. |
| Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 6 | Week 6 | Assessment of the cognitive domain working memory through yes or no responses to 30 trials within 5 minutes; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses. |
| Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 1 | Week 1 | Assessment of the cognitive domain episodic memory through yes or no responses within 5 minutes to 4 targets repeated among 6 distractors on 4 rounds (mild Alzheimer's disease \[AD\], or 3 targets repeated among 4 distractors on 4 rounds (moderate AD) ; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses. |
| Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 3 | Week 3 | Assessment of the cognitive domain episodic memory through yes or no responses within 5 minutes to 4 targets repeated among 6 distractors on 4 rounds (mild Alzheimer's disease \[AD\], or 3 targets repeated among 4 distractors on 4 rounds (moderate AD) ; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses. |
| Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 6 | Week 6 | Assessment of the cognitive domain episodic memory through yes or no responses within 5 minutes to 4 targets repeated among 6 distractors on 4 rounds (mild Alzheimer's disease \[AD\], or 3 targets repeated among 4 distractors on 4 rounds (moderate AD) ; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses. |
| Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 1 | Week 1 | Assessment of the cognitive domain visual attention through a yes or no response to 30 trials within 5 minutes; score range: 0 to 3.69. Performance variable: speed of performance; average log10 transformed reaction time for correct responses. Reaction times longer than 5 seconds ( log10 \[5000\]) were excluded as reflecting responses that were abnormally slow. |
| Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 3 | Week 3 | Assessment of the cognitive domain visual attention through a yes or no response to 30 trials within 5 minutes; score range: 0 to 3.69. Performance variable: speed of performance; average log10 transformed reaction time for correct responses. Reaction times longer than 5 seconds ( log10 \[5000\]) were excluded as reflecting responses that were abnormally slow. |
| Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 6 | Week 6 | Assessment of the cognitive domain visual attention through a yes or no response to 30 trials within 5 minutes; score range: 0 to 3.69. Performance variable: speed of performance; average log10 transformed reaction time for correct responses. Reaction times longer than 5 seconds ( log10 \[5000\]) were excluded as reflecting responses that were abnormally slow. |
| Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 6 | Week 6 | Assessment of the cognitive domain visual episodic memory (associate learning) through responses within 7 minutes to 4 targets x 4 rounds (mild AD) or 3 targets x 4 rounds (moderate AD); score range: 35 to 100. Performance variable: number of errors made in correctly placing each of the 4 patterns in their location four times. |
Countries
South Korea
Participant flow
Pre-assignment details
Each participant was to complete a 3-week placebo run-in period then receive a treatment sequence of either varenicline followed by placebo, or placebo followed by varenicline, separated by a 3-week placebo washout period. Of 92 participants screened, 66 participants were randomized to treatment.
Participants by arm
| Arm | Count |
|---|---|
| Varenicline Then Placebo Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks; then placebo once daily for 1 week followed by placebo BID for 5 weeks. | 32 |
| Placebo Then Varenicline Placebo twice a day (BID) initiated with a 2-week titration regimen (Week 1: once a day \[QD\]; Week 2: BID), followed by varenicline 1 mg BID initiated with a 2-week titration regimen (Week 1: 0.5 mg QD; Week 2: 0.5 mg BID). | 34 |
| Total | 66 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Period 1 | Adverse Event | 4 | 0 |
| Period 1 | Lost to Follow-up | 1 | 0 |
| Period 1 | Other | 0 | 2 |
| Period 1 | Randomized but not Treated | 1 | 1 |
| Period 1 | Withdrawal by Subject | 0 | 2 |
| Period 2 | Adverse Event | 0 | 1 |
Baseline characteristics
| Characteristic | Varenicline Then Placebo | Placebo Then Varenicline | Total |
|---|---|---|---|
| Age Continuous | 71.5 years STANDARD_DEVIATION 8.7 | 73.9 years STANDARD_DEVIATION 5.8 | 72.7 years STANDARD_DEVIATION 7.4 |
| Sex: Female, Male Female | 21 Participants | 21 Participants | 42 Participants |
| Sex: Female, Male Male | 11 Participants | 13 Participants | 24 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 56 / 60 | 37 / 59 |
| serious Total, serious adverse events | 2 / 60 | 0 / 59 |
Outcome results
Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 6
12-item scale to assess severity of cognitive impairment in AD. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, remembering test instructions, and concentration/distractibility. Total score range from 0-75 with 75 indicating worse cognition.
Time frame: Week 6
Population: Full analysis set (FAS): all participants who were randomized and took at least 1 dose of randomized study medication. N = number of participants with ADAS-Cog 75 results at Week 6.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Varenicline | Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 6 | 18.07 units on scale | Standard Error 0.942 |
| Placebo | Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 6 | 18.49 units on scale | Standard Error 0.939 |
Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 3
11-item scale designed to assess the severity of cognitive impairments in AD subjects. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, and remembering test instructions. Total score range from 0-70 with 70 indicating worse cognition.
Time frame: Week 3
Population: FAS. N = number of participants with ADAS-Cog 70 results at Week 3.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Varenicline | Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 3 | 19.60 units on scale | Standard Error 0.88 |
| Placebo | Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 3 | 19.01 units on scale | Standard Error 0.885 |
Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 6
11-item scale designed to assess the severity of cognitive impairments in AD subjects. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, and remembering test instructions. Total score range from 0-70 with 70 indicating worse cognition.
Time frame: Week 6
Population: FAS. N = number of participants with ADAS-Cog 70 results at Week 6.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Varenicline | Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 6 | 17.86 units on scale | Standard Error 0.886 |
| Placebo | Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 6 | 18.23 units on scale | Standard Error 0.884 |
Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 3
12-item scale to assess severity of cognitive impairment in AD. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, remembering test instructions, and concentration/distractibility. Total score range from 0-75 with 75 indicating worse cognition.
Time frame: Week 3
Population: FAS; N = number of participants with ADAS-Cog 75 results at Week 3.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Varenicline | Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 3 | 19.87 units on scale | Standard Error 0.935 |
| Placebo | Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 3 | 19.31 units on scale | Standard Error 0.941 |
Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 1
Assessment of the cognitive domain visual episodic memory (associate learning) through responses within 7 minutes to 4 targets x 4 rounds (mild AD) or 3 targets x 4 rounds (moderate AD); score range: 35 to 100. Performance variable: number of errors made in correctly placing each of the 4 patterns in their location four times.
Time frame: Week 1
Population: FAS; N = number of participants with a CogState score for Continuous Paired Associate Learning at Week 1.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Varenicline | Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 1 | 38.52 errors | Standard Error 2.586 |
| Placebo | Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 1 | 40.05 errors | Standard Error 2.626 |
Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 3
Assessment of the cognitive domain visual episodic memory (associate learning) through responses within 7 minutes to 4 targets x 4 rounds (mild AD) or 3 targets x 4 rounds (moderate AD); score range: 35 to 100. Performance variable: number of errors made in correctly placing each of the 4 patterns in their location four times.
Time frame: Week 3
Population: FAS; N = number of participants with a CogState score for Continuous Paired Associate Learning at Week 3.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Varenicline | Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 3 | 39.43 errors | Standard Error 2.6 |
| Placebo | Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 3 | 43.57 errors | Standard Error 2.656 |
Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 6
Assessment of the cognitive domain visual episodic memory (associate learning) through responses within 7 minutes to 4 targets x 4 rounds (mild AD) or 3 targets x 4 rounds (moderate AD); score range: 35 to 100. Performance variable: number of errors made in correctly placing each of the 4 patterns in their location four times.
Time frame: Week 6
Population: FAS; N = number of participants with a CogState score for Continuous Paired Associate Learning at Week 6.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Varenicline | Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 6 | 41.67 errors | Standard Error 2.668 |
| Placebo | Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 6 | 42.98 errors | Standard Error 2.641 |
Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 1
Assessment of the cognitive domain psychomotor function through yes or no responses within 5 minutes to 30 trials; score range: 0 to 3.69. Performance variable: speed of performance; average of the log10 t transformed reaction time for correct responses. Reaction times longer than 5 seconds (log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.
Time frame: Week 1
Population: FAS; N = number of participants with a CogState score for Detection at Week 1.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Varenicline | Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 1 | 2.65 log10 millisecond | Standard Error 0.015 |
| Placebo | Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 1 | 2.64 log10 millisecond | Standard Error 0.015 |
Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 3
Assessment of the cognitive domain psychomotor function through yes or no responses within 5 minutes to 30 trials; score range: 0 to 3.69. Performance variable: speed of performance; average of the log10 t transformed reaction time for correct responses. Reaction times longer than 5 seconds (log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.
Time frame: Week 3
Population: FAS; N = number of participants with a CogState score for Detection at Week 3.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Varenicline | Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 3 | 2.65 log10 millisecond | Standard Error 0.015 |
| Placebo | Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 3 | 2.63 log10 millisecond | Standard Error 0.015 |
Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 6
Assessment of the cognitive domain psychomotor function through yes or no responses within 5 minutes to 30 trials; score range: 0 to 3.69. Performance variable: speed of performance; average of the log10 t transformed reaction time for correct responses. Reaction times longer than 5 seconds (log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.
Time frame: Week 6
Population: FAS; N = number of participants with a CogState score for Detection at Week 6.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Varenicline | Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 6 | 2.64 log10 millisecond | Standard Error 0.015 |
| Placebo | Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 6 | 2.65 log10 millisecond | Standard Error 0.015 |
Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 1
Assessment of the cognitive domain visual attention through a yes or no response to 30 trials within 5 minutes; score range: 0 to 3.69. Performance variable: speed of performance; average log10 transformed reaction time for correct responses. Reaction times longer than 5 seconds ( log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.
Time frame: Week 1
Population: FAS; N = number of participants with a CogState score for Identification at Week 1.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Varenicline | Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 1 | 2.79 log10 millisecond | Standard Error 0.011 |
| Placebo | Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 1 | 2.80 log10 millisecond | Standard Error 0.011 |
Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 3
Assessment of the cognitive domain visual attention through a yes or no response to 30 trials within 5 minutes; score range: 0 to 3.69. Performance variable: speed of performance; average log10 transformed reaction time for correct responses. Reaction times longer than 5 seconds ( log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.
Time frame: Week 3
Population: FAS; N = number of participants with a CogState score for Identification at Week 3.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Varenicline | Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 3 | 2.79 log10 millisecond | Standard Error 0.011 |
| Placebo | Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 3 | 2.80 log10 millisecond | Standard Error 0.011 |
Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 6
Assessment of the cognitive domain visual attention through a yes or no response to 30 trials within 5 minutes; score range: 0 to 3.69. Performance variable: speed of performance; average log10 transformed reaction time for correct responses. Reaction times longer than 5 seconds ( log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.
Time frame: Week 6
Population: FAS; N = number of participants with a CogState score for Identification at Week 6.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Varenicline | Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 6 | 2.79 log10 millisecond | Standard Error 0.012 |
| Placebo | Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 6 | 2.79 log10 millisecond | Standard Error 0.011 |
Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 1
Assessment of the cognitive domain working memory through yes or no responses to 30 trials within 5 minutes; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.
Time frame: Week 1
Population: FAS; N = number of participants with a CogState score for One Back Working Memory at Week 1.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Varenicline | Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 1 | 0.94 arcsine proportion correct | Standard Error 0.031 |
| Placebo | Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 1 | 0.94 arcsine proportion correct | Standard Error 0.031 |
Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 3
Assessment of the cognitive domain working memory through yes or no responses to 30 trials within 5 minutes; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.
Time frame: Week 3
Population: FAS; N = number of participants with a CogState score for One Back Working Memory at Week 3.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Varenicline | Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 3 | 0.96 arcsine proportion correct | Standard Error 0.031 |
| Placebo | Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 3 | 0.97 arcsine proportion correct | Standard Error 0.032 |
Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 6
Assessment of the cognitive domain working memory through yes or no responses to 30 trials within 5 minutes; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.
Time frame: Week 6
Population: FAS; N = number of participants with a CogState score for One Back Working Memory at Week 6.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Varenicline | Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 6 | 0.95 arcsine proportion correct | Standard Error 0.032 |
| Placebo | Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 6 | 0.96 arcsine proportion correct | Standard Error 0.031 |
Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 1
Assessment of the cognitive domain episodic memory through yes or no responses within 5 minutes to 4 targets repeated among 6 distractors on 4 rounds (mild Alzheimer's disease \[AD\], or 3 targets repeated among 4 distractors on 4 rounds (moderate AD) ; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.
Time frame: Week 1
Population: FAS; N = number of participants with a CogState score for Visual Learning at Week 1.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Varenicline | Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 1 | 0.83 arcsine proportion correct | Standard Error 0.015 |
| Placebo | Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 1 | 0.81 arcsine proportion correct | Standard Error 0.016 |
Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 3
Assessment of the cognitive domain episodic memory through yes or no responses within 5 minutes to 4 targets repeated among 6 distractors on 4 rounds (mild Alzheimer's disease \[AD\], or 3 targets repeated among 4 distractors on 4 rounds (moderate AD) ; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.
Time frame: Week 3
Population: FAS; N = number of participants with a CogState score for Visual Learning at Week 3.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Varenicline | Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 3 | 0.82 arcsine proportion correct | Standard Error 0.016 |
| Placebo | Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 3 | 0.82 arcsine proportion correct | Standard Error 0.016 |
Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 6
Assessment of the cognitive domain episodic memory through yes or no responses within 5 minutes to 4 targets repeated among 6 distractors on 4 rounds (mild Alzheimer's disease \[AD\], or 3 targets repeated among 4 distractors on 4 rounds (moderate AD) ; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.
Time frame: Week 6
Population: FAS; N = number of participants with a CogState score for Visual Learning at Week 6.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Varenicline | Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 6 | 0.83 arcsine proportion correct | Standard Error 0.016 |
| Placebo | Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 6 | 0.84 arcsine proportion correct | Standard Error 0.016 |
Mean Clinical Global Impression - Improvement (CGI-I) Score at Week 6
CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.
Time frame: Week 6
Population: FAS; N = number of participants with a CGI-I score at Week 6.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Varenicline | Mean Clinical Global Impression - Improvement (CGI-I) Score at Week 6 | 3.71 units on a scale | Standard Error 0.103 |
| Placebo | Mean Clinical Global Impression - Improvement (CGI-I) Score at Week 6 | 3.70 units on a scale | Standard Error 0.102 |
Neuropsychiatric Inventory (NPI) Total Score at Week 3
Caregiver interview-based rating scale assessing 12 behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, appetite/eating, and sleep. Each symptom score derived by frequency of symptoms \* severity of symptoms (range 0-12). Total score = sum of symptom scores; range: 0-144 with higher score indicating greater behavioral disturbances.
Time frame: Week 3
Population: FAS. N = number of participants with a NPI total score at Week 3.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Varenicline | Neuropsychiatric Inventory (NPI) Total Score at Week 3 | 2.97 scores on scale | Standard Error 0.845 |
| Placebo | Neuropsychiatric Inventory (NPI) Total Score at Week 3 | 2.29 scores on scale | Standard Error 0.858 |
Neuropsychiatric Inventory (NPI) Total Score at Week 6
Caregiver interview-based rating scale assessing 12 behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, appetite/eating, and sleep. Each symptom score derived by frequency of symptoms \* severity of symptoms (range 0-12). Total score = sum of symptom scores; range: 0-144 with higher score indicating greater behavioral disturbances.
Time frame: Week 6
Population: FAS. N = number of participants with a NPI total score at Week 6.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Varenicline | Neuropsychiatric Inventory (NPI) Total Score at Week 6 | 3.82 scores on scale | Standard Error 0.857 |
| Placebo | Neuropsychiatric Inventory (NPI) Total Score at Week 6 | 2.55 scores on scale | Standard Error 0.855 |